Eli Lilly and Company has announced plans to invest more than $6 billion in a new small-molecule active pharmaceutical ingredient (API) and peptide manufacturing facility in Huntsville, Alabama. The expansion is part of the company’s multi-year $50-billion investments in US capital expansion commitments made since 2020.  

This facility is the third of four new US sites Lilly that Lilly has announced. It will be among those that will manufacture orforglipron, Lilly’s oral, small molecule GLP-1 receptor agonist, which the company expects to submit to global regulatory agencies for obesity by the end of this year (2025). Construction is expected to begin in 2026, with completion slated for 2032. 

The new facility is the next in Lilly’s US expansion plan, first announced in February 2025. It joins Lilly’s previously announced investments in Texas, Virginia, and Puerto Rico, broken down as follows: 

• $5 billion for a new Virginia API and drug product manufacturing facility, including for the company’s emerging bioconjugate platform and monoclonal antibody portfolio;  

• $6.5 billion for a new Texas small-molecule API manufacturing facility; 

• $1.2 billion in  Puerto Rico to expand an existing facility for oral solid medicines. 

Lilly says that another US location will be announced in the coming weeks (as reported on December 9, 2025). 

Source: Eli Lilly and Company